Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases

Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases
A combination of Bristol-Myers Squibb’s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor burden in castration-resistant prostate cancer patients whose tumors have spread, interim Phase 2 results show. Findings from the CheckMate 650 trial (NCT02985957) were recently shared at the 2019 Genitourinary Cancers Symposium in San Francisco in a presentation titled, “Initial results from a phase II study of ni
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *